Is Biocure Technology Inc. (BICTF) a Buy, Sell, or Hold?
Biocure Technology Inc.
OTC:BICTF
$0.01 USD
$0 (0.0%)
- Volume
- 1K
- Average Volume
- 644
- Market Capitalization
- $379.09K
- P/E Ratio
- -2.10
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $0.07
- Year Low
- $0.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.10
Industry, Sector & symbol
| Stock Exchange | OTC |
| CEO | Yee Sing Cheng |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | BICTF |
| CUSIP | 09075T206 |
| CIK | None |
| Web | https://www.biocuretech.com |
| Phone | +1 604 507 1797 |
| Currency | USD |
| Employees | 3 |
| Country | CA |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 0.10 |
| Quick Ratio | 0.10 |
| Cash Ratio | 0.10 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | 0.00 |
| Price / Cash Flow | -7.10 |
| Price / Book | 0.18 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 0 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.0064 |
| Trailing P/E Ratio | -2.10 |
| PEG Ratio | 0.07 |
| P/E Growth | 0.07 |
| Net Income | $-102.78K |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -6.94% |
| Return on Assets | -5.12% |
Financials Score
| AltmanZ Score | -16.32 |
| Piotroski Score | 4.00 |
| Working Capital | -389.22K |
| Total Assets | 2.01M |
| Ebit | -97.29K |
| Market Cap | 536.61K |
| Total Liabilities | 434.66K |
Poll Results
About Biocure Technology Inc. (OTC:BICTF) Stock
Biocure Technology Inc., along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis. They are also developing Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related ocular condition known as macular edema. Furthermore, Biocure is progressing Filgrastim, a treatment for neutropenia—a deficiency of white blood cells often resulting from cancer, bone marrow transplantation, chemotherapy, or other health issues. Beyond these, Biocure Technology is actively engaged in the research and development of innov ... ative CAR T Cell therapy, intended to pinpoint and destroy cancer cells. Their investigative efforts also encompass a vaccine for foot and mouth disease and a variety of hair growth solutions. Established in 2005, the company's main operations are situated in Vancouver, Canada.
Biocure Technology Inc. Announces Adoption of Semi-Annual Reporting
2026-05-08 16:15:00
Vancouver, B.C. – TheNewswire - May 8, 2026 ‐ Biocure Technology Inc. (CSE: CURE) (OTCQB: BICTF) (the “ Company” or “Biocure”) announces the adoption of semi-annual financial reporting. This news release is being filed pursuant to Coordinated Blanket Order 51 – 933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers (“ CBO 51-933 ”). CBO 51-933 allows eligible venture issuers to voluntarily move from a quarterly to a semi-annual financial reporting framework. Biocure's fiscal year ends on December 31. Under the provisions of CBO 51-933, Biocure will be exempt from the requirements to file its three-month interim financial statements and associated management's discussion and analysis (“ MD&A ”) as it meets the eligibility criteria under CBO 51-933, which include being a venture issuer with annual revenues of less than $10 million and maintaining a clean 12-month continuous disclosure record. Accordingly, Biocure will not be filing its interim financial statements for the three-month period ending March 31, 2026 and associated MD&A.
Frequently Asked Questions
-
What is the current Biocure Technology Inc. (BICTF) stock price?
-
Biocure Technology Inc.(OTC:BICTF) stock price is $0.01 in the last trading session. During the trading session, BICTF stock reached the peak price of $0.07 while $0.01 was the lowest point it dropped to. The percentage change in BICTF stock occurred in the recent session was 0.0% while the dollar amount for the price change in BICTF stock was $0.
-
BICTF's industry and sector of operation?
-
The OTC listed BICTF is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of BICTF?
-
Marco Nonni | Consultant
Konstantin Lichtenwald | Chief Financial Officer, Corporate Secretary & Director
Yee Sing Cheng | Chief Executive Officer & Director
|
| -
How many employees does BICTF have?
-
Number of BICTF employees currently stands at 3. BICTF operates from 1055 West Hastings Street, Vancouver, BC V6E 2E9, CA.
-
Link for BICTF official website?
-
Official Website of BICTF is: https://www.biocuretech.com
-
How do I contact BICTF?
-
BICTF could be contacted at phone #+1 604 507 1797 and can also be accessed through its website. BICTF operates from 1055 West Hastings Street, Vancouver, BC V6E 2E9, CA.
-
How many shares of BICTF are traded daily?
-
The average number of BICTF shares traded daily for last 3 months was 644.
-
What is the market cap of BICTF currently?
-
The market value of BICTF currently stands at $379.09K with its latest stock price at $0.01